Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Cited by (1,001)

Items 601–700 of 1,001

1. Ibrutinib’s off-target mechanism: cause for dose optimization
   Sara M. Zimmerman, Cody J. Peer, William Douglas Figg · 2021 · Cancer Biology & Therapy
2. Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets
   Ti’ara L. Griffen, Fieke W. Hoff, Yihua Qiu, James W. Lillard, Alessandra Ferrajoli, Philip A. Thompson, Endurance Toro, Kevin Ruiz, Jan A. Burger, William G. Wierda et al. · 2022 · Blood Cancer Journal
3. Bruton's TK Inhibitors: Structural Insights and Evolution of Clinical Candidates
   Li Xing, Adrian J. Huang · 2014 · Future Medicinal Chemistry
4. Chronic lymphocytic leukemia therapy: new targeted therapies on the way
   Candida Vitale, Jan A. Burger · 2016 · Expert Opinion on Pharmacotherapy
5. Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
   G.A. Amos Burke, Auke Beishuizen, Deepa Bhojwani, Birgit Burkhardt, Véronique Minard‐Colin, Robin Elizabeth Norris, Edita Kabíčková, Faruk Güçlü Pınarlı, Nurdan Taçyıldız, Angela J. Howes et al. · 2020 · Leukemia
6. A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis
   Sang Eun Yoon, Seok Jin Kim, Dok Hyun Yoon, Youngil Koh, Yeung‐Chul Mun, Young Rok Do, Yoon Seok Choi, Deok‐Hwan Yang, Min Kyoung Kim, Gyeong‐Won Lee et al. · 2020 · Annals of Hematology
7. Ibrutinib
   Mark‐Alexander Schwarzbich, Mathias Witzens‐Harig · 2014 · Recent results in cancer research/Recent Results in Cancer Research
8. Disruption of pre-B-cell receptor signaling jams the WNT/β-catenin pathway and induces cell death in B-cell acute lymphoblastic leukemia cell lines
   Nakhle S. Saba, Magdalena Angelova, Patricia Lobelle‐Rich, Laura Silven Levy · 2015 · Leukemia Research
9. Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model
   Wei Du, Rebecca Goldstein, Yanwen Jiang, Omar Aly, Leandro C. A. Cerchietti, Ari M. Melnick, Olivier Elemento · 2017 · Cancer Research
10. 17p Deletion in Chronic Lymphocytic Leukemia
    Andrea Schnaiter, Stephan Stilgenbauer · 2013 · Hematology/Oncology Clinics of North America
11. Formation of CYP3A ‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio
    Jonghwa Lee, John K. Fallon, Philip C. Smith, Klarissa D. Jackson · 2022 · Clinical and Translational Science
12. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
    Sumukh Arun Kumar, Jenny Gao, Shyam Ajay Patel · 2023 · Leukemia Research
13. Novel Treatment Options for Waldenström Macroglobulinemia
    Houry Leblebjian, Amit Agarwal, Irene M. Ghobrial · 2013 · Clinical Lymphoma Myeloma & Leukemia
14. Clinical Efficacy and Management of Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma
    Bertrand Coiffier · 2013 · Clinical Lymphoma Myeloma & Leukemia
15. VII. Management of nodular lymphocyte‐predominant Hodgkin lymphoma
    Dennis Alexander Eichenauer, Andreas Engert · 2013 · Hematological Oncology
16. Treatment of chronic lymphocytic leukemia in older adults
    Rachael B. Rowswell-Turner, Paul M. Barr · 2017 · Journal of Geriatric Oncology
17. The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
    Alessandro Noto, Ramona Cassin, Veronica Mattiello, Gianluigi Reda · 2021 · Journal of Clinical Medicine
18. Risk of bleeding associated with BTK inhibitor monotherapy: a systematic review and meta-analysis of randomized controlled trials
    Dan Li Jiang, Zaiwei Song, Yang Hu, Fei Dong, Rongsheng Zhao · 2022 · Expert Review of Clinical Pharmacology
19. Management of mantle cell lymphoma in the elderly patient
    Hanneke C. Kluin‐Nelemans, Jeanette K. Doorduijn · 2013 · Clinical Interventions in Aging
20. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia
    Shin‐ichiro Fujiwara, Yuya Shirato, Takashi Ikeda, Shin‐ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shinichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino et al. · 2017 · International Journal of Hematology
21. Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
    Georg Heß, Karola Wagner, Ulrich Bernd Keller, Paul Graf La Rosée, Johannes Atta, Kai Hübel, Christian Lerchenmueller, Daniel Schoendube, Mathias Witzens‐Harig, Christian Ruckes et al. · 2020 · HemaSphere
22. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
    Anna Wolska, Tadeusz Robak · 2022 · Expert Review of Hematology
23. Ibrutinib‐induced severe liver injury
    Amara Gayathri Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram · 2017 · Clinical Case Reports
24. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
    Patricia Balsas, Anna Esteve‐Arenys, Jocabed Roldán, L. Jiménez, Vanina Rodríguez, Juan García Valero, Aránzazu Chamorro-Jorganes, Raimon Puig de la Bellacasa, Jordi Teixidó, Alba Matas‐Céspedes et al. · 2017 · Journal of Hematology & Oncology
25. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression
    Simona Gambino, Francesca Maria Quaglia, Marilisa Galasso, Chiara Cavallini, Roberto Chignola, Ornella Lovato, Luca Giacobazzi, Simone Caligola, Annalisa Adamo, Santosh Putta et al. · 2024 · Scientific Reports
26. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice
    Natalia Timofeeva, Nitin Jain, Varsha V. Gandhi · 2024 · Blood Neoplasia
27. MYD88 L265P mutation in cutaneous involvement by Waldenström macroglobulinemia
    Victoria Alegría‐Landa, Lucía Prieto‐Torres, Carlos Santonja, Raúl Córdoba, Rebeca Manso, Luís Requena, Socorro Marıá Rodríguez-Pinilla · 2017 · Journal of Cutaneous Pathology
28. Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
    Donato Mannina, Barbara Loteta · 2017 · Case Reports in Hematology
29. No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
    Song Mu, Börje Darpö, Zhiyu Tang, William F. Novotny, Manal Tawashi, Hongqi Xue, Michael S. Willett, Leo Y.-C. Lin, Sri Sahasranaman, Ying C. Ou · 2020 · Clinical and Translational Science
30. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells
    Meihui Xia, Tina YuXuan Luo, Yonghong Shi, Guizhi Wang, Hubert Tsui, Daniel Harari, David Spaner · 2020 · The Journal of Immunology
31. Negative innovation: when patents are bad for patients
    Robin Feldman, David A. Hyman, W. Nicholson Price, Mark J. Ratain · 2021 · Nature Biotechnology
32. Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia
    Leigh Naylor‐Adamson, Anisha R Chacko, Zoe Booth, Stefano Caserta, Jenna Jarvis, Sujoy Khan, Simon Paul Hart, Francisco Rivero, David John Allsup, Mònica Arman · 2021 · Frontiers in Immunology
33. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
    Javier L Munoz, Shayna Sarosiek, Jorge Julio Castillo · 2023 · The Oncologist
34. Treatment Strategies in Mantle Cell Lymphoma
    Kami J. Maddocks, Kristie A. Blum · 2015 · Cancer treatment and research
35. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies
    Francesco F. Zaja, Massimo Federico, Umberto Vitolo, Pier Luigi Zinzani · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
36. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies
    BING XIA, Fulian Qu, Yuan Tian, Yizhuo Zhang · 2015 · Oncology Letters
37. Targeting oncogenic and epigenetic survival pathways in lymphoma
    Lori Ann Leslie, Anas Younes · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
38. Management of marginal zone lymphoma.
    Robin M. Reid, Jonathan W. Friedberg · 2013 · PubMed
39. Frontline strategy for follicular lymphoma: are we ready to abandon chemotherapy?
    Nathan Hale Fowler · 2016 · Hematology
40. Ocular adnexal lymphomas: a review
    Huw Richards, Conor M. Ramsden, Rosalina Naidoo, Camille Yvon, Elizabeth Jacob, Sajir G. Mohamedbhai · 2017 · Expert Review of Ophthalmology
41. Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review
    Zhaohuan Li, Zengjuan Zheng, Chenglei Li, Zhipeng Li, Jingliang Wu, Bo Zhang · 2020 · Journal of drug targeting
42. Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
    Tingting Yang, Weihao Chen, Yanmin Zhao, Huarui Fu, He Huang, Jimin Shi · 2021 · Frontiers in Oncology
43. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    James Bryant Collins, Sarah E. Stump, Hillary Heiling, Michele Muir, Allison Mary Deal, Darrian Proco, Catharine Nguyen, Monica Cozad, Anthony R. Mato, Catherine Callaghan Coombs et al. · 2022 · Leukemia & lymphoma/Leukemia and lymphoma
44. Chronische lymphatische Leukämie
    Stephan Stilgenbauer, Michael J. Hallek · 2013 · Der Internist
45. Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
    Alexandra Albertsson‐Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek · 2019 · Experimental Hematology and Oncology
46. Transformed Lymphoma
    Mary Ann Anderson, Piers A. Blombery, John Francis Seymour · 2016 · Hematology/Oncology Clinics of North America
47. Case 01-2017—Primary vitreoretinal lymphoma (PVRL): report of a case and update of literature from 1942 to 2016
    Yujuan Wang, Dik S. Cheung, Chi‐Chao Chan · 2017 · Annals of Eye Science
48. Acalabrutinib for adults with mantle cell lymphoma
    Wojciech J. Jurczak, Monika Długosz‐Danecka, Michael L. Wang · 2019 · Expert Review of Clinical Pharmacology
49. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open‐Label, Phase 1 Study
    David A. Martin, Jean‐Baptiste Telliez, Susan Pleasic‐Williams, Ying Zhang, Brendan Tierney, Matthew Blatnik, Jeremy D. Gale, Chris Banfield, Yifan Zhou, Alexandre Lejeune et al. · 2023 · The Journal of Clinical Pharmacology
50. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway
    Chunyan Wu, Shilv Chen, Zhimin Wu, Xue Jiao, Wen Zhang, Shan Wang, Xindong Zhao, Shao-Ling Wu · 2024 · Journal of Cancer Research and Clinical Oncology
51. Computational Investigation of the Covalent Inhibition Mechanism of Bruton’s Tyrosine Kinase by Ibrutinib
    Angela M. Barragan, Kyle Ghaby, Matthew P. Pond, Benoı̂t Roux · 2024 · Journal of Chemical Information and Modeling
52. Advances in Primary Central Nervous System Lymphoma
    Kate Elizabeth Therkelsen, Antonio M. P. Omuro · 2024 · Current Neurology and Neuroscience Reports
53. BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma
    Matthew J. Carter, Kerry L. Cox, Stuart James Blakemore, Yury D. Bogdanov, Lina Happo, Clare L. Scott, Andreas Strasser, Graham Packham, Mark Steven Cragg · 2015 · Cell Death and Differentiation
54. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
    Januario E. Castro, Michael Y. Choi, Tomás Carvajal, Eiman A. Almahasnah, John T. Chang, Danelle Frances James, Thomas J. Kipps · 2014 · Blood Cancer Journal
55. Possible novel agents in marginal zone lymphoma
    Pier Luigi Zinzani, Alessandro Broccoli · 2016 · Best Practice & Research Clinical Haematology
56. An Internally Controlled Quantitative Target Occupancy Assay for Covalent Inhibitors
    Rasmus Hansen, Sarah J. Firdaus, Shuangwei Li, Matthew Robert Janes, Jingchuan Zhang, Yi Liu, Patrick P. Zarrinkar · 2018 · Scientific Reports
57. The role of acalabrutinib in adults with chronic lymphocytic leukemia
    Bita Fakhri, Charalambos Babis Andreadis · 2021 · Therapeutic Advances in Hematology
58. Chronic lymphocytic leukemia in a young population
    Salem Alshemmari, Abdulaziz Hamdah, Ramesh Pandita, Anita Kunhikrishnan · 2021 · Leukemia Research
59. Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
    Ajoy Dias, Dharamvir Jain · 2014 · Cardiovascular & Hematological Agents in Medicinal Chemistry
60. Ibrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
    Gretchen A McNally, Jennifer M. Long, Lynne Brophy, Maria Badillo · 2015 · Journal of the Advanced Practitioner in Oncology
61. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment
    Prashant Kapoor, Stephen M. Ansell, Esteban Braggio · 2016 · Cancer treatment and research
62. Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015
    Randy D. Gascoyne, Bertrand Nadel, Laura Pasqualucci, Jude Fitzgibbon, Jacqueline E. Payton, Ari M. Melnick, Oliver Weigert, Karin Tarte, John G. Gribben, Jonathan W. Friedberg et al. · 2017 · Hematological Oncology
63. The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia
    Andrew Aw, Jennifer R. Brown · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
64. Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia
    Gayane P. Manukyan, Peter Turcsányi, Zuzana Mikulková, Gabriela Gabčová, Renata Urbanová, Petr Gajdoš, Veronika Šmotková Kraiczová, Šárka Zehnalová, Tomáš Papajík, Eva Kriegová · 2018 · Leukemia Research
65. Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells
    Yonghong Shi, Guizhi Wang, Elizabeth M. Muhowski, Lindsay McCaw, Catherine Wang, Georg A. Bjarnason, Jennifer Ann Woyach, David Spaner · 2019 · Leukemia
66. Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma
    Makhdum Ahmed, Elizabeth Lorence, Jeffrey Wang, Dayoung Jung, Liang Zhang, Krystle J. Nomie, Michael L. Wang · 2019 · Science Signaling
67. Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma
    Zhuojun Liu, Jia Liu, Tianming Zhang, Lin Li, Shuo Zhang, Hao Jia, Yuanshi Xia, Mingxia Shi, Jing Zhang, Shuhua Yue et al. · 2021 · BMC Cancer
68. Bruton Tyrosine Kinase Inhibitors for the Frontline Treatment of Chronic Lymphocytic Leukemia
    Versha Banerji, Andrew Aw, Sperry Robinson, Sarah Doucette, Anna Christofides, Laurie Helen Sehn · 2020 · Current Oncology
69. Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
    Xin Xu, Ting Wei, Weijie Zhong, Rosalind L. Ang, Lei Ye, Hui Zhang, Qingshan Li · 2021 · Cancer Cell International
70. Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
    H. Huber, Simone Edenhofer, Sven Estenfelder, Stephan Stilgenbauer · 2017 · OncoTargets and Therapy
71. Advances in Classification and Treatment of Non-Hodgkin Lymphoma
    Simon A. Rule, Sophie Johns · 2020 · The Cancer Journal
72. Determining drug dose in the era of targeted therapies: playing it (un)safe?
    Sigrid Strand Skånland, Geir Erland Tjønnfjord · 2022 · Blood Cancer Journal
73. Synthesis of novel cyanopyridine compounds as potential EGFR inhibitors targeting A549 and PC3 cancer cell lines: In vitro, In vivo and ADME pharmacokinetics studies
    Elsayed Hussein Mostafa Eltamany, Shrouk M. Shaban, Ahmed T. A. Boraei, Emad M. Gad, Mohamed S. Nafie · 2024 · Journal of Molecular Structure
74. Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
    Alessandro Broccoli, Marzia Del Re, Romano Danesi, Pier Luigi Zinzani · 2025 · Journal of Cellular and Molecular Medicine
75. Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery
    Sarah Lynn Ondrejka, Eric D. Hsi · 2015 · Cancer treatment and research
76. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib
    David D. Smith, Leanne Goldstein, Mei L. Cheng, Danelle Frances James, Lori Kunkel, Maria Fardis, Ahmed Hamdy, Raquel E. Izumi, Joseph J. Buggy, Fong Clow · 2014 · Annals of Hematology
77. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma
    Alberto Mussetti, Anita Ashok Kumar, Parastoo Bahrami Dahi, Miguel‐Angel Perales, Craig Steven Sauter · 2014 · Blood Reviews
78. Developing Novel Strategies to Target B-Cell Malignancies
    Nathan Hale Fowler, Yasuhiro Oki · 2013 · American Society of Clinical Oncology Educational Book
79. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma
    Mark J. Roschewski, Kieron M. Dunleavy, Wyndham Hopkins Wilson · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
80. Ibrutinib for the treatment of mantle cell lymphoma
    Nimish Shah, Claire V. Hutchinson, Simon A. Rule · 2014 · Expert Review of Hematology
81. Efficacy of ibrutinib in a patient with transformed lymphoplasmacytic lymphoma and central nervous system involvement
    Laura S. Hiemcke‐Jiwa, Roos J. Leguit, Joyce H. Radersma‐van Loon, Peter E. Westerweel, Johannes J.M. Rood, Jeanette K. Doorduijn, Manon M. H. Huibers, Monique C. Minnema · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
82. Ibrutinib: from bench side to clinical implications
    Davide Grisafi, Alessandra Maestro, Camilla Grumi, L. Piazzoni, Giampaolo Tirone, Walter Fiore, Roberto Tessari, Valeria Gianardi, Milo Gatti, Francesca Tasca et al. · 2015 · Medical Oncology
83. Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise
    Foluso Nelson Ogunleye, Alexander Glick, Michael Stender, Ishmael A. Jaiyesimi · 2015 · Clinical Lymphoma Myeloma & Leukemia
84. Kinase Inhibitors in Cancer
    Andrew A. Mortlock, Kevin M. Foote, Jason G. Kettle, Brian M. Aquila · 2014 · Elsevier eBooks
85. Targeting protein kinase C in mantle cell lymphoma
    Hilka Rauert‐Wunderlich, Martina Rudelius, German Ott, Andreas Rosenwald · 2016 · British Journal of Haematology
86. Managing early failures with R-CHOP in patients with diffuse large B-cell lymphoma
    Vincent Camus, Hervé Tilly · 2016 · Expert Review of Hematology
87. Treatment approaches of hard-to-treat non-Hodgkin lymphomas
    Lakshminarayanan Nandagopal, Amitkumar Mehta · 2017 · Expert Review of Hematology
88. From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research
    Allen S. Lichter · 2018 · Journal of Clinical Oncology
89. Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects
    Prashant S. Kharkar · 2020 · Current Topics in Medicinal Chemistry
90. Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase
    Xiaoyu Wang, Zhe Wang, Xiaoyu Fan, Mingrui Yan, Lili Jiang, Yangliu Xia, Jun Cao, Yong Liu · 2021 · Toxicology and Applied Pharmacology
91. The New Treatment Methods for Non-Hodgkin Lymphoma in Pediatric Patients
    Justyna Derebas, Kinga Panuciak, Mikołaj Margas, Joanna Zawitkowska, Monika Lejman · 2022 · Cancers
92. New insights, recent advances, and current challenges in the biological treatment of multiple myeloma
    Sonia Vallet, Klaus Podar · 2013 · Expert Opinion on Biological Therapy
93. Bruton's tyrosine kinase inhibitors
    Loïc Ysebaert, Anne‐Sophie Michallet · 2014 · Current Opinion in Oncology
94. Efficient synthesis of (S)-N-Boc-3-hydroxypiperidine using an (R)-specific carbonyl reductase from Candida parapsilosis
    Jingjing Chen, Ming Yan, Lin Xu · 2017 · World Journal of Microbiology and Biotechnology
95. In vitro metabolism of ibrutinib in rat, dog and human hepatocytes using liquid chromatography combined with diode‐array detection and Q‐Exactive Orbitrap tandem mass spectrometry
    Jiangnan Dong, Li Su, Guangxuan Liu · 2019 · Rapid Communications in Mass Spectrometry
96. Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
    Koji Izutsu, Kiyoshi Ando, Daisuke Ennishi, Hirohiko Shibayama, Junji Suzumiya, Kazuhito Yamamoto, Satoshi Ichikawa, Koji Kato, Kyoya Kumagai, Priti S. Patel et al. · 2021 · Cancer Science
97. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop
    Michael E. Williams, Steven H. Bernstein, Pedro Jares, Brad S. Kahl, Thomas Elmer Witzig, Leo I. Gordon · 2013 · Leukemia & lymphoma/Leukemia and lymphoma
98. Evaluation of Bruton’s Tyrosine Kinase (BTK) inhibition with alternative doses of ibrutinib in subjects with Chronic Lymphocytic Leukemia (CLL)
    Aziz Ouerdani, Belén Valenzuela, Nicoline Treijtel, Nahor Haddish‐Berhane, Sanjay Desphande, Srimathi S. Srinivasan, Emma Smith, Juan José Pérez Ruixo · 2025 · Cancer Chemotherapy and Pharmacology
99. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Gaurav Varma, Tyler Paul Johnson, Ranjana H. Advani · 2016 · PubMed
100. B cell receptor inhibition as a target for CLL therapy
     Deepa Jeyakumar, Susan Mary O'Brien · 2016 · Best Practice & Research Clinical Haematology